Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase III trial - Kato, K; Cho, B; Takahashi, M (Lancet Oncol, 2019)
et al.